Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett’s esophagus
| Autor: | Adam Fabisiak, Jakub Fichna, Adrian Bartoszek, Grzegorz Kardas, Natalia Fabisiak |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Esophageal Neoplasms Physiology 030209 endocrinology & metabolism Stratified squamous epithelium Adenocarcinoma Biochemistry Gastroenterology Barrett Esophagus 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Endocrinology Trefoil Factors Internal medicine Biomarkers Tumor medicine Humans Esophagus business.industry Heartburn Intestinal metaplasia medicine.disease humanities digestive system diseases medicine.anatomical_structure Dysplasia Barrett's esophagus Gastroesophageal Reflux GERD Biomarker (medicine) medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Peptides. 115:27-31 |
| ISSN: | 0196-9781 |
| DOI: | 10.1016/j.peptides.2019.02.007 |
| Popis: | Gastroesophageal reflux disease (GERD) is a chronic disorder of the digestive tract characterised mainly by a heartburn. Being one of the most common gastrointestinal diseases, the prevalence of GERD reaches up to 25.9% in Europe. Barrett's esophagus (BE) is an acquired condition characterized by the replacement of the normal stratified squamous epithelium with metaplastic columnar epithelium. BE is believed to develop mainly from chronic GERD and is the most important risk factor of esophageal adenocarcinoma. Despite the availability of drugs such as proton pomp inhibitors and antacids, GERD is still a burden to local economy and impairs health-related quality of life in patients. Also, the endoscopic surveillance in patients with BE is burdensome and expensive what drives the need for biomarker of intestinal metaplasia and dysplasia. Trefoil factor family (TFF), consisting of TFF1, TFF2 and TFF3 peptides is gaining more and more attention due to its unique biochemical features and numerous functions. In this review the role of TFF1, TFF2 and TFF3 as potential treatment option and/or biomarker in the upper GI tract is discussed with particular focus on GERD and BE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect